143 related articles for article (PubMed ID: 14967819)
1. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells.
Liu YY; Han TY; Yu JY; Bitterman A; Le A; Giuliano AE; Cabot MC
J Lipid Res; 2004 May; 45(5):933-40. PubMed ID: 14967819
[TBL] [Abstract][Full Text] [Related]
2. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
[TBL] [Abstract][Full Text] [Related]
3. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance.
Liu YY; Han TY; Giuliano AE; Hansen N; Cabot MC
J Biol Chem; 2000 Mar; 275(10):7138-43. PubMed ID: 10702281
[TBL] [Abstract][Full Text] [Related]
4. A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.
Patwardhan GA; Zhang QJ; Yin D; Gupta V; Bao J; Senkal CE; Ogretmen B; Cabot MC; Shah GV; Sylvester PW; Jazwinski SM; Liu YY
PLoS One; 2009 Sep; 4(9):e6938. PubMed ID: 19742320
[TBL] [Abstract][Full Text] [Related]
5. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
[TBL] [Abstract][Full Text] [Related]
6. Ceramide glycosylation potentiates cellular multidrug resistance.
Liu YY; Han TY; Giuliano AE; Cabot MC
FASEB J; 2001 Mar; 15(3):719-30. PubMed ID: 11259390
[TBL] [Abstract][Full Text] [Related]
7. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells.
Siddiqui A; Patwardhan GA; Liu YY; Nazzal S
Int J Pharm; 2010 Nov; 400(1-2):251-9. PubMed ID: 20816930
[TBL] [Abstract][Full Text] [Related]
8. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
[TBL] [Abstract][Full Text] [Related]
9. A role for ceramide in driving cancer cell resistance to doxorubicin.
Liu YY; Yu JY; Yin D; Patwardhan GA; Gupta V; Hirabayashi Y; Holleran WM; Giuliano AE; Jazwinski SM; Gouaze-Andersson V; Consoli DP; Cabot MC
FASEB J; 2008 Jul; 22(7):2541-51. PubMed ID: 18245173
[TBL] [Abstract][Full Text] [Related]
10. [Investigation on the relationship between multidrug resistance and expression of glucosylceramide synthase in human breast carcinoma cells].
Sun YL; Zhou GY; Li KN; Guo CH; Gao P; Lin XY
Zhonghua Bing Li Xue Za Zhi; 2005 Feb; 34(2):109-10. PubMed ID: 15842808
[No Abstract] [Full Text] [Related]
11. Ceramide reduction and transcriptional up-regulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells.
Uchida Y; Itoh M; Taguchi Y; Yamaoka S; Umehara H; Ichikawa S; Hirabayashi Y; Holleran WM; Okazaki T
Cancer Res; 2004 Sep; 64(17):6271-9. PubMed ID: 15342415
[TBL] [Abstract][Full Text] [Related]
12. MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells.
Zhang X; Wu X; Li J; Sun Y; Gao P; Zhang C; Zhang H; Zhou G
J Surg Oncol; 2011 Oct; 104(5):466-71. PubMed ID: 21538359
[TBL] [Abstract][Full Text] [Related]
13. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells.
Liu YY; Han TY; Giuliano AE; Cabot MC
J Biol Chem; 1999 Jan; 274(2):1140-6. PubMed ID: 9873062
[TBL] [Abstract][Full Text] [Related]
14. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
[TBL] [Abstract][Full Text] [Related]
15. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells.
Lavie Y; Cao Ht; Volner A; Lucci A; Han TY; Geffen V; Giuliano AE; Cabot MC
J Biol Chem; 1997 Jan; 272(3):1682-7. PubMed ID: 8999846
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
Shabbits JA; Mayer LD
Mol Cancer Ther; 2002 Jan; 1(3):205-13. PubMed ID: 12467215
[TBL] [Abstract][Full Text] [Related]
17. Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells.
Sun YL; Zhou GY; Li KN; Gao P; Zhang QH; Zhen JH; Bai YH; Zhang XF
Neoplasma; 2006; 53(1):1-8. PubMed ID: 16416005
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy.
Gouazé V; Yu JY; Bleicher RJ; Han TY; Liu YY; Wang H; Gottesman MM; Bitterman A; Giuliano AE; Cabot MC
Mol Cancer Ther; 2004 May; 3(5):633-9. PubMed ID: 15141021
[TBL] [Abstract][Full Text] [Related]
19. [Construction of glucosylceramide synthase-specific siRNA expression vector and its efficiency in reversal of drug resistance in breast carcinoma cells].
Sun YL; Zhou GY; Li KN; Li WT; Song XR; Gao P
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):518-21. PubMed ID: 15949329
[TBL] [Abstract][Full Text] [Related]
20. Resistance to the antiproliferative effect induced by a short-chain ceramide is associated with an increase of glucosylceramide synthase, P-glycoprotein, and multidrug-resistance gene-1 in cervical cancer cells.
Gutiérrez-Iglesias G; Hurtado Y; Palma-Lara I; López-Marure R
Cancer Chemother Pharmacol; 2014 Oct; 74(4):809-17. PubMed ID: 25113261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
